Product Name: EGFR-pT678
Product Number: AB-PK120
Size: 25 µg      Price:89.00
      $US
Target Full Name: Receptor protein-tyrosine kinase epidermal growth factor receptor Thr-678 phosphosite

Target Alias: Avian erythroblastic leukemia viral (v-erb-b) oncogene homologue; Cell growth inhibiting protein 40; cell proliferation-inducing protein 61; ERBB; ERBB1; HER1; mENA; PIG61; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

Product Type Specific: Phosphosite-specific polyclonal antibody for human EGFR T678 phosphosite

Antibody Code: PK120

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: T678

Protein UniProt: P00533

Protein SigNET: P00533

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Ig Isotype Clone: IgG

Antibody Immunogen Source: Peptide with amino acid sequence surrounding the human EGFR Thr-678 phospho-site (Lys-Arg-pThr-Leu-Arg)

Antibody Immunogen Sequence: KRpTLR

Antibody Immunogen Description: 5 amino acid phosphopeptide corresponding to the human EGFR T678 phosphosite

Production Method: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

Antibody Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol

Storage Conditions: -20°C

Storage Stability: > 1 year

Product Use: Western blotting

Antibody Dilution Recommended: 2 µg/mL

Antibody Potency: Very strong

Antibody Species Reactivity: Human, Mouse, Rat

Antibody Positive Control: T678 phosphorylated EGFR

Antibody Specificity: Very high

Antibody Cross Reactivity: No strong cross-reactivities with other proteins.

Scientific Background: EGFR is a receptor-tyrosine kinase for epidermal growth factor (EGF) and related growth factors including Transforming growth factor (TGF)-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor. EGFR is involved in the control of cell growth and differentiation. Ligand binding to this receptor results in receptor dimerization, autophosphorylation (in trans), activation of various downstream signaling molecules and lysosomal degradation. It can be phosphorylated and activated by Src. Activated EGFR binds to the SH2 domain of phospholipase C-gamma (PLC-gamma) and activates downstream signaling from this phospholipase. Grb2 and SHC bind to phospho-EGFR and are involved in the activation of MAP kinase signaling pathways. Phosphorylation on Ser and Thr residues appears to attenuate of EGFR kinase activity. Phosphorylated EGFR binds Cbl, leading to its ubiquitination and degradation. Four alternatively spliced isoforms have been described with molecular masses of 134,277, 77,312, 69,288 and 44,664 Da. EGFR is unbiquitously expressed in normal tissues, and overexpressed in breast, head and neck cancers, which correlated with poor survival. Activating somatic mutations are seen in lung cancer, which in a minority of patients with strong responses to the EGFR inhibitor Iressa (Gefitinib, ZD1839). Other inhibitors include Erbitux, Tarceva, and Lapatinib.
Figure 1. Immunoblotting of various cell lines with AB-PK120 antibody at a 500 X dilution. The target protein EGFR is indicated. Each lane was loaded with 15 µg of cell lysate protein. The max signal count was 43466.


Figure 2. Immunoblotting of various cell lines with AB-PK120 antibody at a 500 X dilution. The target protein EGFR is indicated. Each lane was loaded with 15 µg of cell lysate protein. The max signal count was 52658.